Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients

Hamzehzadeh, Leila; Khadangi, Fatemeh; Karimiani, Ehsan Ghayoor; Pasdar, Alireza; Kerachian, Mohammad Amin

doi:10.1016/j.currproblcancer.2018.05.001

Cited by 20 publications

(30 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KRAS and BRAF mutation detection. All samples were tested for the most common and known KRAS and BRAF mutations for exon 12 and 15, respectively based on a protocol previously published 48,49 . The details are described in Supplementary Fig.…”

Section: Biological Validation Tissue Validationmentioning

confidence: 99%

Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor

Kerachian

Javadmanesh

Azghandi

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Colorectal cancer (CRC), the second leading cause of cancer mortality, constitutes a significant global health burden. An accurate, noninvasive detection method for cRc as complement to colonoscopy could improve the effectiveness of treatment. In the present study, SureSelectXT Methyl-Seq was performed on cancerous and normal colon tissues and CLDN1, INHBA and SLC30A10 were found as candidate methylated genes. MethyLight assay was run on formalin-fixed paraffin-embedded (FFPE) and fresh case and control tissues to validate the methylation of the selected gene. the methylation was significantly different (p-values < 2.2e-16) with a sensitivity of 87.17%; at a specificity cut-off of 100% in FFPE tissues. Methylation studies on fresh tissues, indicated a sensitivity of 82.14% and a specificity cut-off of 92% (p-values = 1.163e-07). The biomarker performance was robust since, normal tissues indicated a significant 22.1-fold over-expression of the selected gene as compared to the corresponding CRC tissues (p-value < 2.2e-16) in the FFPE expression assay. In our plasma pilot study, evaluation of the tissue methylation marker in the circulating cell-free DNA, demonstrated that 9 out of 22 CRC samples and 20 out of 20 normal samples were identified correctly. In summary, there is a clinical feasibility that the offered methylated gene could serve as a candidate biomarker for CRC diagnostic purpose, although further exploration of our candidate gene is warranted.Colorectal cancer (CRC) constitutes a significant global health burden, leading to over 862,000 deaths globally in 2018. It is the second main cause of cancer mortality in the world and currently stands as the third most common cancer, with a yearly incidence of over one million and eight thousand cases worldwide 1 . Its leading cause of death is due to liver metastasis with a median survival rate of approximately 30 months. Generally, half of the patients with CRC develop tumor recurrences 2 . For early-diagnosed CRC patients, the 5-year survival rates are approximately 90% but this lowers to less than 10% in patients with extensive metastases. Thus, the most effective approach to reduce CRC incidence and its mortality is early detection of colonic lesions 3 . Fortunately, because of implementation and growth of wide spread cancer screening assays, such as colonoscopy as well as increasingly effective therapies, the mortality rate of CRC is lowering in many countries 2 .

show abstract

Section: Biological Validation Tissue Validationmentioning

confidence: 99%

Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor

Kerachian

Javadmanesh

Azghandi

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fu X et al [6], found KRAS exon 2 mutation rates were 37.7% in 5546 CRC patients diagnosed from 2010 to 2017. guo F et al [7], KRAS exon 2 mutations were identified in 42.2% in 353 CRC patients from two Chinese clinical centers. Hamzehzadeh l et [8], detected mutations in exon 2 (codons 12 and 13) of the KRAS and NRAS genes using high resolution melting analysis, ıntplex design and Sanger sequencing in 87 ıranian CRC patients. genomic DNA was isolated from fresh tissue samples of CRC patients.…”

Section: Frequency Of Kras Mutations Among Patients With Crcmentioning

confidence: 99%

KRAS gene mutation in patients with primary colorectal cancer

Thi¹,

Le²,

Huynh³

et al. 2019

Acta Medica

View full text Add to dashboard Cite

Objective: KRAS mutation occurs in 30% to 50% of colorectal cancers. The aim of our study was to determine the frequency of KRAS mutations among patients with colorectal cancer; and the relationship with clinicopathologic features. Materials and Methods: 79 colorectal cancer cases at a hospital in Hai Phong of Vietnam were collected, including 45 colon cancer and 34 rectal cancer during January 2010 and July 2012. PCR amplification and DNA sequencing were used to detect mutations in exon 2 of KRAS gene. The study was based on informed consent and approval by the Ethics Committee of Viet Tiep Hospital. Results: KRAS mutation was found in 40.4% (225/557) colorectal cancer. All mutation locations were in codon 12. There was significant association (p < 0.05) between KRAS mutations, tumor size and tumor stage. No significant association was observed between KRAS mutations and gender, tumor location, tumor grade or histologic presence of mucin (p>0.05). Conclusion: Determining the KRAS mutational status of tumor samples has become an essential tool for managing patients with colorectal cancers Keywords: colorectal cancer, KRAS gene mutation, clinicopathology.

show abstract

“…Mutation detection was performed with a clinical validated approach based on the allele-specific qPCR intplex method [ 8 ]. PCR cycling analysis was conducted on LightCycler ® 96 Real-Time PCR System.…”

Section: Main Textmentioning

confidence: 99%

Simple and cost-effective laboratory methods to evaluate and validate cell-free DNA isolation

et al. 2018

Self Cite

View full text Add to dashboard Cite

ObjectiveIn the present study, we investigated different simple and cost effective methods to evaluate and validate cell free DNA (cfDNA) isolation. The ability of the QIAamp DNA Blood Mini Kit method to extract cfDNA was assessed by several approaches, including purification of endogenous cfDNA and exogenous spike-in control material, prior to plasma extraction, and followed by quantitative-PCR.ResultsUsing QIAamp DNA Blood Mini kit, nearly 27% (380 bp) to 35% (173 bp) cfDNA was recovered with a higher recovery of smaller size cfDNA (173 bp) in comparison to larger ones (380 bp). These simple laboratory methods can be used to assess the efficiency of any cfDNA isolation method.Electronic supplementary materialThe online version of this article (10.1186/s13104-018-3866-8) contains supplementary material, which is available to authorized users.

show abstract

Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients

Cited by 20 publications

References 37 publications

Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor

Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor

KRAS gene mutation in patients with primary colorectal cancer

Simple and cost-effective laboratory methods to evaluate and validate cell-free DNA isolation

Contact Info

Product

Resources

About